Aura Biosciences Announces Interim Phase 1b/2 Data on Light-Activated AU-011 for Primary Ocular Melanoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura announced interim safety data from an open-label Phase 1b/2 study of its lead program, light-activated AU-011 for primary ocular melanoma.